RT Journal Article
SR Electronic
T1 Prevalence of differences of sex development in Switzerland from 2000-2019
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.03.11.24304115
DO 10.1101/2024.03.11.24304115
A1 Metzger, Sara
A1 Sommer, Grit
A1 Flück, Christa E.
A1 ,
YR 2024
UL http://medrxiv.org/content/early/2024/03/13/2024.03.11.24304115.abstract
AB Objective Reliable data on prevalence of rare differences of sex development (DSD) are lacking. We aimed to estimate population-based prevalence of DSD in Switzerland.Design Retrospective population-based study including individuals with DSD according to Chicago Consensus, born in Switzerland from 2000-2019.Methods Endocrine care centers in all ten Swiss Children’s Hospitals and eight private endocrine practices collected DSD data through the I-DSD registry or case report forms. We calculated prevalence for DSD diagnostic groups and analyzed time trends in prevalence.Results Over the 20-year study period, we identified 561 individuals with DSD. Almost half (n=266, 47%) had sex chromosome DSD, 177 (32%) had 46,XY DSD and 118 (21%) had 46, XX DSD. Causes for 46,XY DSD were disturbed androgen synthesis or action (37/177, 21%), atypical gonadal development (28/177, 16%), or other causes (112/177, 63%). Causes for 46,XX DSD were androgen excess (99/118, 84%), atypical gonadal development (8/118, 7%), or other causes (11/118, 9%). On average, 28 new cases were born with DSD annually. Prevalence was 17 for sex chromosome DSD, 12 for 46,XY DSD and 8 for 46,XX DSD per 100’000 live births and year. One per 7,500 newborn girls had 46,XX congenital adrenal hypoplasia (CAH).Conclusion Prevalence of sex chromosome DSD was lower than expected because of underreporting due to late diagnosis. Prevalence of 46,XX CAH is similar to newborn screening data, suggesting good completeness of cases. For complex DSD cases, we expect complete coverage. This study provides a valuable resource for policymaking and (inter)national research on DSD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Swiss Society of Endocrinology and Diabetology (SGED), by the Boveri Foundation Zurich and by the "Stiftung Kinderinsel".Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of the Canton of Bern granted ethical approval to the Swiss DSD Cohort Study under BASEC ID 2016-01210.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData of this study are registered in the I-DSD Registry and can be accessed upon request. I-DSD governance and rules apply, see https://sdmregistries.org/.